ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jul 19, 2021 09:03 JST
Source:
Eisai
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
TOKYO, Jul 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand. This is the first launch of Goofice in the Asian region excluding Japan.
Goofice, which Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. (Tokyo, "EA Pharma"), in-licensed from Albireo AB (Sweden), is a once-daily, orally available constipation treatment with a novel action mechanism. Goofice inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon. The dual action of moisture secretion and bowel movement promotion is expected to enhance natural defecation.
The prevalence of constipation is high in young women as well as in both elderly men and women. In Thailand, the number of patients with the prevalence of self-defined constipation is estimated to be about 10 million1, and it is predicted that the number of patients will increase year by year as the population ages. In constipation, symptoms such as sensation of incomplete evacuation and hard stools appear in addition to reduction of bowel movement frequency. When such symptoms become chronic, many patients suffer a decline in QOL (quality of life).
In Japan, EA Pharma and Mochida Pharmaceutical Co., Ltd. (Tokyo) respectively market the product under the same brand name, and Eisai is co-promoting with EA Pharma. In Asia (Thailand, Indonesia, Philippines, Malaysia, and Singapore), Eisai is responsible for the commercialization and marketing of this product under a contract with EA Pharma.
Eisai will continue to make a further contribution to improve QOL for patients with chronic constipation in Thailand and other Asian countries, through maximization of the product value of Goofice.
Source: Eisai
Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Fujitsu Limited announces recruitment plans
Mar 19, 2024 10:34 JST
Nissan and Mitsubishi Corporation agree to explore new business in next-generation-mobility and energy-related services utilizing EVs
Mar 18, 2024 17:29 JST
Fujitsu and AWS will launch a new Modernization Acceleration Joint Initiative to enable customers across industries to drive digital transformation with fast and secure legacy modernization
Mar 18, 2024 16:12 JST
Nissan and Honda to start feasibility study of strategic partnership
Mar 18, 2024 12:14 JST
Mitsubishi Power Achieves #1 Global Gas Turbine Market Share in 2023
Mar 15, 2024 18:34 JST
Mitsubishi Corp to invest in TIER IV: Transforming regional mobility with autonomous driving
Mar 15, 2024 12:36 JST
Hitachi High-Tech Launches High-sensitivity and High-throughput Wafer Surface Inspection System LS9300AD for Wafer Manufacturers
Mar 15, 2024 11:21 JST
Japanese joint research group win Prime Minister's Award with ultra high-performance computing platform using jointly developed 64-qubit quantum computer
Mar 15, 2024 10:19 JST
MHI Establishes GX Solutions Business Domain to Promote Energy Transition Business Growth Strategy
Mar 14, 2024 13:30 JST
Fujitsu and Tokai National Higher Education and Research System collaborate on AI-based space weather research
Mar 14, 2024 10:21 JST
Mitsubishi Corporation, Mitsubishi Fuso Truck and Bus, and Mitsubishi Motors will jointly establish a new company to run an online platform providing comprehensive EV related services
Mar 13, 2024 18:06 JST
MHI Selected as Licensor of CO2 Capture Technology for Leading Low Carbon Hydrogen Production Project in Cheshire, UK
Mar 13, 2024 11:30 JST
GMO Research Activity Support & Technology launches brain MRI analysis tool developed on world class supercomputer Fugaku with Fujitsu Computing as a Service (CaaS)
Mar 12, 2024 10:20 JST
TANAKA Establishes Bonding Technology for High-Density Semiconductor Mounting Using AuRoFUSE(TM) Preforms
Mar 12, 2024 03:00 JST
Hitachi Forges a Three Year Strategic Alliance with AWS to Advance Hybrid Cloud Solutions
Mar 11, 2024 16:44 JST
MHI Thermal Systems to Launch 31 Models of Residential-use Air-Conditioners for the Japanese Market in 2024
Mar 11, 2024 16:35 JST
The Future of Accessibility: Toyota Mobility Foundation and MaRS Discovery District Launch the Mobility Unlimited Hub in Toronto
Mar 08, 2024 10:35 JST
Lucas GC Limited (NASDAQ: LGCL) Harnesses AI and GPT Technologies to Drive Human Resources Services and ESG Compliance
Mar 07, 2024 12:48 JST
NEC named to list of Top 100 Global Innovators by Clarivate for 13th consecutive year
Mar 07, 2024 11:24 JST
Fujitsu and Carnegie Mellon University develop AI-powered social digital twin technology with traffic data from Pittsburgh
Mar 07, 2024 10:25 JST
More Latest Release >>
Related Release
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
3/6/2024 5:47:00 PM JST
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
2/21/2024 3:26:00 PM JST
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2024 9:35:00 AM JST
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
2/16/2024 9:31:00 AM JST
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
2/1/2024 6:04:00 PM JST
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
1/26/2024 4:26:00 PM JST
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
1/18/2024 3:12:00 PM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
1/17/2024 5:08:00 PM JST
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
1/16/2024 10:25:00 AM JST
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
1/11/2024 4:33:00 PM JST
More Press release >>